Lipocine Announces Financial and Operational Results for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Lipocine Announces Financial and Operational Results for the First Quarter of 2015

SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq: LPCN ), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2015, as well as recent operational highlights.

Quarterly and Recent Highlights

  • Completed the last patient visit in the safety assessment portion of its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study ( http://clinicaltrials.gov/show/NCT02081300 ) evaluating efficacy and safety of LPCN 1021, its Oral Testosterone product for hypogonadal men with low testosterone. Lipocine previously announced positive top line efficacy from the SOAR clinical study in September 2014 and expects to announce top-line results from the 52 week safety assessment portion of the SOAR clinical study by mid-year, as well as file the New Drug Application ("NDA") with the U.S. Food and Drug Administration in the second half of this year.
  • Completed an underwritten public offering of 5,347,500 shares of its common stock at $6.50 per share for gross proceeds of $34.8 million. Lipocine received net proceeds of approximately $32.5 million, after deducting the underwriters' discounts and other estimated offering expenses.
  • Completed its pre-NDA meeting with the U.S. Food and Drug Administration ("FDA") related to LPCN 1021. Based on the FDA's preliminary response, Lipocine does not expect to conduct any additional clinical studies other than the on-going labeling "food effect" study which has always been required for the expected submission of the NDA. Lipocine is conducting the labeling "food effect" study per the FDA requirement and plans to submit preliminary results from this study to the FDA in the second quarter of 2015 for review and comment prior to submitting the NDA.
  • Presented additional data from its ongoing SOAR pivotal Phase 3 clinical study evaluating efficacy and safety of LPCN 1021 at both the American Society of Andrology 40th Annual Conference in Salt Lake City, Utah and the ENDO 2015 in San Diego, CA.
  • Announced successful top-line results of a Phase 1b study of LPCN 1107, its oral hydroxyprogesterone caproate ("HPC") product candidate. Results from this study demonstrated significant HPC absorption following oral administration in healthy pregnant women. In this study, LPCN 1107 was well tolerated with no serious adverse events observed. Lipocine has requested a meeting with the FDA and expects to provide guidance on the development plan for LPCN 1107 in the second quarter of 2015.  
  • Presented data from a successful Phase 1a study of LPCN 1107 at the Society for Maternal-Fetal Medicine 35th Annual Meeting in San Diego, CA. The study was designed to determine the pharmacokinetics and bioavailability of LPCN 1107 relative to an intramuscular (IM) HPC, as well as safety and tolerability, in healthy non-pregnant female volunteers.
  • Completed a Phase 2a clinical study of LPCN 1111, a next-generation novel testosterone TRT product candidate, in hypogonadal males with Low T. Based on these positive results, a Phase 2b study is expected to begin in the fourth quarter of 2015 or the first quarter of 2016 with the objective of determining the optimal once daily dosing regimen of LPCN 1111.

"The beginning of 2015 has been an eventful period for Lipocine, with FDA interaction, multiple data presentations and continued progress with our lead product, LPCN 1021, and our other clinical programs," said Dr. Mahesh Patel, President and CEO of Lipocine Inc. "In addition, the recent completion of our public offering has strengthened our balance sheet and provides us with the necessary capital to accelerate development of our earlier clinical assets."

First Quarter 2015 Financial Results

Lipocine reported a net loss of $3.0 million, or $0.23 per diluted share, for the first quarter of 2015, compared with a net loss of $5.3 million, or $0.41 per diluted share, for the first quarter of 2014.

For the first quarter of 2015, research and development expenses were $1.9 million, compared with $3.4 million for the first quarter of 2014. The decrease was largely attributable to decreased external service provider costs related to clinical research and contract manufacturing and also reduced internal personnel costs.

For the first quarter of 2015, general and administrative expenses were $1.1 million, compared with $1.9 million for the same period in 2014. The decrease was primarily due to accelerated vesting and extension of exercise dates from retiring directors in the 2014 period and also reduced legal and accounting fees. This was partially offset by a slight increase in other personnel costs.

As of March 31, 2015, Lipocine had cash and cash equivalents of $24.8 million, compared with cash and cash equivalents of $27.7 million as of December 31, 2014. This does not include the net proceeds of $32.5 million from the public offering we completed on April 29, 2015, as this occurred subsequent to the quarter end.

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's lead product candidate, LPCN 1021, demonstrated positive top-line efficacy results in Phase 3 testing and is targeted for testosterone replacement therapy, or TRT. Additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing, that is currently in Phase 2 testing, and LPCN 1107, which has the potential to become the first oral hydroxyprogesterone caproate (HPC) product indicated for the prevention of recurrent preterm birth, is currently in Phase 1 testing.

Forward-Looking Statements

This release contains "forward looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts relating to an underwritten public offering of Lipocine's common stock, clinical trials, the potential uses and benefits of Lipocine's product candidates, and product development and commercialization efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks related to market conditions for Lipocine's common stock, the failure to satisfy offering conditions, the risks related to the receipt of regulatory approvals, the results of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q and the final prospectus supplement which will be filed with the SEC, all of which can be obtained on the SEC website at www.sec.gov . Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

LIPOCINE INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
     
  Three Months Ending March 31,
  2015 2014
     
Operating expenses:    
Research and development  $ 1,918,695  $ 3,368,999
General and administrative  1,055,544  1,923,623
Total operating expenses  2,974,239  5,292,622
Operating loss  (2,974,239)  (5,292,622)
Other income, net  18,633  25,466
Loss before income tax expense  (2,955,606)  (5,267,156)
Income tax expense  (200)  --
Net loss  $ (2,955,806)  $ (5,267,156)
     
Basic loss per share attributable to common stock  $ (0.23)  $ (0.41)
     
Weighted average common shares outstanding, basic  12,819,332  12,728,086
     
Diluted loss per share attributable to common stock   $ (0.23)  $ (0.41)
     
Weighted average common shares outstanding, diluted  12,819,332  12,728,086
     
Comprehensive loss  $ (2,955,806)  $ (5,267,156)
 
 
LIPOCINE INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited)
     
  March 31, December 31,
  2015 2014
Assets    
Current assets:    
Cash and cash equivalents  $ 24,764,456  $ 27,666,055
Prepaid and other current assets  186,462  229,912
Total current assets  24,950,918  27,895,967
     
Property and equipment, net of accumulated depreciation of $1,038,332 and $1,034,029, respectively  82,709  73,782
Other assets  23,753  23,753
Total assets  $ 25,057,380  $ 27,993,502
     
     
Liabilities and Stockholders' Equity    
Current liabilities:    
Accounts payable  $ 379,528  $ 306,276
Accrued expenses  957,777  1,327,256
Total current liabilities  1,337,305  1,633,532
Total liabilities  1,337,305  1,633,532
     
Commitments and contingencies    
     
Stockholders' equity:    
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized; zero issued and outstanding  --  --
Common stock, par value $0.0001 per share, 100,000,000 shares authorized; 12,850,090 and 12,800,382 issued and 12,844,380 and 12,794,672 outstanding  1,285  1,280
Additional paid-in capital  94,952,385  94,636,479
Treasury stock at cost, 5,710 shares  (40,712)  (40,712)
Accumulated deficit  (71,192,883)  (68,237,077)
Total stockholders' equity  23,720,075  26,359,970
     
Total liabilities and stockholders' equity  $ 25,057,380  $ 27,993,502

Morgan Brown Executive Vice President & Chief Financial Officer Phone: (801) 994-7383 Email: John Woolford Phone: (443) 213-0500

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 44

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 0

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 119

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 25

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 5

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 81

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 91

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
Wall Street Gains Hold Amid Volatility Drop

Updated Category News Views 66

A Week of Gains and Regulatory Moves Right out of the gate, it’s been a decent stretch for Wall Street. Weekly gains kept the party going, even as traders navigated the usual hurdles. Stocks finished the week with a solid performance—all the heavy hitters like Dow, S&P 500, Nasdaq, and Russell 2000 ended on a high note, waltzing uphill past where many imagined...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 154

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 82

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading

Top 5 Most Recently Viewed Articles

Dr. Moumine Ballo: Trailblazer in Electronics and Graphics

Updated Category News Views 256

Acknowledging Dr. Moumine Ballo's Influence in Technology Dr. Moumine Ballo has recently been honored as a Pinnacle Professional Member Inner Circle of Excellence, a testimony to his exceptional contributions in the fields of Computer Graphics and Electronics Engineering. With over three decades of experience, Dr. Ballo's impact in technology is both profound and...

Continue Reading
SolePursuit Capital Syndicate's Commitment to Governance Growth

Updated Category News Views 190

Introduction to Governance and Transparency Updates SolePursuit Capital Syndicate has taken significant strides in enhancing its governance framework and transparency protocols. Under the leadership of founder Laurence Kingsley, the organization recently shared its Annual Governance and Transparency Update. This document sheds light on the important advancements made in...

Continue Reading
Omni Family Institute's Program Achieves Major Regulatory Recognition

Updated Category News Views 228

Omni Family Institute Celebrates Program Recognition Omni Family Institute, a respected organization committed to trauma-informed care, proudly announces the recent acknowledgment of its flagship initiative, Together Facing the Challenge. This program has successfully achieved a 'Supported' rating from the Title IV-E Prevention Services Clearinghouse, a notable milestone...

Continue Reading
Ideal Power's Q3 2025 Financial Updates and Future Plans

Updated Category News Views 185

Company Overview Ideal Power Inc. (NASDAQ: IPWR) is a pioneering developer and provider of innovative semiconductor solutions, specializing in the B-TRAN® bidirectional power switch technology. This technology enhances energy efficiency across various applications, including electric vehicles and renewable energy. Milestone Achievements Recently, CEO David Somo expressed...

Continue Reading
Latest Developments Surrounding Meta Platforms Insider Trading

Updated Category News Views 409

Significant Insider Trading at Meta Platforms Meta Platforms, Inc. (NASDAQ: META) has recently caught attention due to a notable action taken by its Chief Product Officer, Christopher K. Cox. It has come to light that Cox sold a substantial 20,000 shares of the company’s Class A Common Stock. This transaction, occurring at a price range of $555.00 to $560.25 per share,...

Continue Reading